DelveInsight’s, “Postmenopausal Osteoporosis - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Postmenopausal Osteoporosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Postmenopausal Osteoporosis: Overview
Osteoporosis is a metabolic bone disorder that is characterized by low bone mass and micro-architectural deterioration of bone tissue. Fractures of the proximal femur, the vertebrae and the distal radius are the most frequent osteoporotic fractures, although most fractures in the elderly are probably at least partly related to bone fragility. The incidence of fractures varies greatly by country, but on average up to 50% of women >50 years of age are at risk of fractures. Fractures severely affect the quality of life of an individual and are becoming a major public health problem owing to the ageing population. Postmenopausal Osteoporosis, resulting from oestrogen deficiency, is the most common type of osteoporosis. Oestrogen deficiency results in an increase in bone turnover owing to effects on all types of bone cells. The imbalance in bone formation and resorption has effects on trabecular bone (loss of connectivity) and cortical bone (cortical thinning and porosity).
"Postmenopausal Osteoporosis - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Postmenopausal Osteoporosis pipeline landscape is provided which includes the disease overview and Postmenopausal Osteoporosis treatment guidelines. The assessment part of the report embraces, in depth Postmenopausal Osteoporosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postmenopausal Osteoporosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Postmenopausal Osteoporosis R&D. The therapies under development are focused on novel approaches to treat/improve Postmenopausal Osteoporosis.
This segment of the Postmenopausal Osteoporosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Postmenopausal Osteoporosis Emerging Drugs
TVB-009: Teva Pharmaceutical
TVB-009 is a Denosumab biosimilar being developed by Teva Pharmaceutical for the treatment of patients with Postmenopausal Osteoporosis. TVB-009 is a RANK ligand inhibitor and is currently in phase 3 of clinical trials.
Blosozumab: Eli Lilly and Company
Blosozumab is a humanised IgG4 monoclonal antibody, being developed by Eli Lilly and Company, for the treatment of Postmenopausal Osteoporosis. It is a SOST protein inhibitor and is currently in phase 2 of clinical trials.
Further product details are provided in the report……..
his segment of the report provides insights about the different Postmenopausal Osteoporosis drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the therapies for Postmenopausal Osteoporosis. The companies which have their Postmenopausal Osteoporosis drug candidates in the most advanced stage, i.e. phase III include, Teva Pharmaceutical.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
Postmenopausal Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Postmenopausal Osteoporosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Postmenopausal Osteoporosis drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Postmenopausal Osteoporosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Postmenopausal Osteoporosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Postmenopausal Osteoporosis Collaboration Deals
Late Stage Products (Phase III)
TVB-009: Teva Pharmaceutical
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Blosozumab: Eli Lilly and Company
Drug profiles in the detailed report…..
Inactive Products
Postmenopausal Osteoporosis Key Companies
Postmenopausal Osteoporosis Key Products
Postmenopausal Osteoporosis- Unmet Needs
Postmenopausal Osteoporosis- Market Drivers and Barriers
Postmenopausal Osteoporosis- Future Perspectives and Conclusion
Postmenopausal Osteoporosis Analyst Views
Postmenopausal Osteoporosis Key Companies
Appendix
List of Figures
Figure 1: Total Products for Postmenopausal Osteoporosis
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Post Menopausal Osteoporosis companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Post Menopausal Osteoporosis Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs
• Teva Pharmaceutical
• Eli Lilly and Company
• Shanghai Biomabs Pharmaceutical
• HEXAL
• Samsung Bioepis
• Qilu Pharmaceutical
• Shenzhen Salubris Pharmaceuticals
• Jiangsu HengRui Medicine Co., Ltd.
• Celltrion
• Mabwell (Shanghai) Bioscience Co., Ltd.
• Huons Co., Ltd.
• Entera Bio Ltd.
• PhytoHealth
• Reliance Life Sciences
• Enteris BioPharma
• Luye Pharma
• Sandoz International GmbH
• Shanghai Henlius Biotech
• Haoma Medica
• Outlook Therapeutics
